|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is typified by midostaurin, which has been approved by the US Food and Drug Administration for mutant FLT3-positive AML and for KIT D816V-positive SM.
|
31309543 |
2019 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In AML cohort of 239 patients, high IL2RA mRNA expression independently predicted shorter relapse free survival (RFS, p < 0.001) and overall survival (OS, p < 0.001) irrespective of age, cytogenetics, FLT3-ITD or c-KIT D816V mutational status.
|
31171000 |
2019 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The oncogenic D816V mutation of the KIT receptor is well characterized in systemic mastocytosis and acute myeloid leukemia.
|
28584020 |
2017 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia.
|
25247397 |
2015 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found the activity of protein phosphatase 2A (PP2A), a human tumor suppressor whose dysfunction contributes to malignant cell behavior, was significantly decreased in AML subgroups harboring C-KIT/D816V and AML cell line Kasumi-1 bearing C-KIT/N822K mutation.
|
22109829 |
2012 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, our data show that AML blasts may lack this transforming target-mutant, which may be important when considering the use of KIT D816V-targeting drugs for treatment of patients with KIT D816V-positive AML.
|
20471335 |
2010 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dasatinib has in vitro and in vivo efficacy in SM-AML patients with KIT(D816V) mutation.
|
18986703 |
2009 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There were no amplifications among 64 KIT wild-type tumors and cell lines, whereas all D816V-mutant samples (eight AML and 11 mast cell disease) were positive.
|
17065430 |
2006 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Because the D816V mutation was detected in the initial bone marrow specimen, strict application of three minor diagnostic criteria (spindling, CD25, D816V) enabled a diagnosis of SM-AML to be confirmed retrospectively in the initial bone marrow tissue.
|
14990611 |
2004 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Substitution of valine (Val) for aspartic acid (Asp) at codon 814 constitutively activates murine c-kit receptor tyrosine kinase (KIT), and Asp816Val mutation, corresponding to murine Asp814Val mutation, is found in patients with mastocytosis and acute myelocytic leukemia.
|
12393643 |
2003 |
|
rs121913507
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val.
|
9858225 |
1998 |